Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay

Blood

Volumn 116, Issue 14, 2010, Pages 2455-2461

  Kristen, Arnt V ^a   Giannitsis, Evangelos ^a   Lehrke, Stephanie ^a   Hegenbart, Ute ^b   Konstandin, Matthias ^a   Lindenmaier, David ^a   Merkle, Corina ^a   Hardt, Stefan ^a   Schnabel, Philipp A ^b   Röcken, Christoph ^c   Schonland, Stefan O ^b   Ho, Anthony D ^b   Dengler, Thomas J ^a   Katus, Hugo A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; TROPONIN T;

ADULT; AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART VENTRICLE SEPTUM; HEART VENTRICLE SEPTUM DEFECT; HUMAN; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SENSITIVITY ANALYSIS; STAGING; SURVIVAL;

EID: 77957735365     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-267708     Document Type: Article

References (40)

1. Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol. 2004;127(5):543-551. (Pubitemid 39627178)
2. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983;58(10):665-683. (Pubitemid 13019381)
3. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78(1):74-82. (Pubitemid 27346885)
4. Kristen AV, Perz JB, Schonland SO, et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant. 2007;26(12):1313-1319.
5. Palladini G, Malamani G, Co F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol. 2001;24(8):1228-1233. (Pubitemid 32756921)
6. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6(4):737-743. (Pubitemid 16247618)
7. Koyama J, Ray Sequin PA, Falk RH. Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation. 2002;106(5):556-561. (Pubitemid 34827704)
8. Kristen AV, Perz J, Schonland S, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9:617-624. (Pubitemid 46702816)
9. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361(9371):1787-1789. (Pubitemid 36638428)
10. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757. (Pubitemid 41095215)
11. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-2445. (Pubitemid 36605226)
12. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation. 2000;102(11):1216-1220.
13. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634-2653.
14. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286(19):2405-2412. (Pubitemid 33098158)
15. Mingels A, Jacobs L, Michielsen E, et al. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem. 2009;55(1):101-108.
16. James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med. 2003;115(3):178-184. (Pubitemid 37338141)
17. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858-867.
18. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868-877.
19. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10(th) International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79(4):319-328. (Pubitemid 41098849)
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
21. Rahman JE, Helou EF, Gelzer Bell R, et al. Non-invasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol. 2004;43(3):410-415.
22. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: I. Diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387-1393.
23. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450-458. (Pubitemid 16119719)
24. Declaration of Helsinki. Recommendations guiding doctors in clinical research: adopted by the World Medical Association in 1964. Wis Med J. 1967;66(1):25-26.
25. Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254-261.
26. Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. Clin Chem. 2008;54(7):1234-1238. (Pubitemid 352009701)
27. Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation. 1991;83(3):902-912.
28. Steen H, Giannitsis E, Futterer S, et al. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol. 2006;48(11):2192-2194. (Pubitemid 44855412)
29. Omland T, De Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361(26):2538-2547.
30. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116(11):1242-1249. (Pubitemid 47517535)
31. Bochtler T, Hegenbart U, Heiss C, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica. 2008;93(3):459-462. (Pubitemid 351398651)
32. Kristen AV, Dengler TJ, Katus HA. Suspected cardiac amyloidosis: endomyocardial biopsy remains the diagnostic gold-standard. Am J Hematol. 2007;82(4):328.
33. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008;49(1):36-41. (Pubitemid 351146880)
34. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid. 2007;14(4):261-269. (Pubitemid 350035577)
35. Goldsmith YB, Liu J, Chou J, et al. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol. 2009;104(7):990-994.
36. Saba N, Sutton D, Ross H, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant. 1999;24(8):853-855. (Pubitemid 29500345)
37. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma. 2008;49(1):36-41. (Pubitemid 351146880)
38. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104(6):1881-1887. (Pubitemid 39202301)
39. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68(1):220-224.
40. Kristen AV, Sack FU, Schonland SO, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail. 2009;11(10):1014-1020.